Acute respiratory failure and diffuse pulmonary infiltrates four weeks after rituximab therapy

Hadi H. Hatoum; George A. Sarosi; Kenneth S. Knox; Chadi A. Hage

doi:10.1016/j.rmedc.2008.12.004

Acute respiratory failure and diffuse pulmonary infiltrates four weeks after rituximab therapy

Hadi H. Hatoum, George A. Sarosi, Kenneth S. Knox, Chadi A. Hage

Research output: Contribution to journal › Article › peer-review

Abstract

We report a 51-year-old woman with known SLE on low dose prednisone, recently started on rituximab, who presents with acute respiratory failure and bilateral air space disease. After an initial treatment with broad spectrum antibiotics for healthcare-associated pneumonia and negative serologic studies, a diagnosis of pneumocystis pneumonia was established using bronchoalveolar lavage. We suggest that rituximab can be an aggravating cause of pneumocystis in patients treated with prednisone.

Original language	English (US)
Pages (from-to)	134-136
Number of pages	3
Journal	Respiratory Medicine CME
Volume	2
Issue number	3
DOIs	https://doi.org/10.1016/j.rmedc.2008.12.004
State	Published - 2009
Externally published	Yes

Keywords

Pneumocystis pneumonia
Rituximab

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.rmedc.2008.12.004

OpenUrl availability

Full text

Cite this

@article{d7888684588d4ebfad538039d114e863,

title = "Acute respiratory failure and diffuse pulmonary infiltrates four weeks after rituximab therapy",

abstract = "We report a 51-year-old woman with known SLE on low dose prednisone, recently started on rituximab, who presents with acute respiratory failure and bilateral air space disease. After an initial treatment with broad spectrum antibiotics for healthcare-associated pneumonia and negative serologic studies, a diagnosis of pneumocystis pneumonia was established using bronchoalveolar lavage. We suggest that rituximab can be an aggravating cause of pneumocystis in patients treated with prednisone.",

keywords = "Pneumocystis pneumonia, Rituximab",

author = "Hatoum, {Hadi H.} and Sarosi, {George A.} and Knox, {Kenneth S.} and Hage, {Chadi A.}",

year = "2009",

doi = "10.1016/j.rmedc.2008.12.004",

language = "English (US)",

volume = "2",

pages = "134--136",

journal = "Respiratory Medicine CME",

issn = "1755-0017",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Acute respiratory failure and diffuse pulmonary infiltrates four weeks after rituximab therapy

AU - Hatoum, Hadi H.

AU - Sarosi, George A.

AU - Knox, Kenneth S.

AU - Hage, Chadi A.

PY - 2009

Y1 - 2009

N2 - We report a 51-year-old woman with known SLE on low dose prednisone, recently started on rituximab, who presents with acute respiratory failure and bilateral air space disease. After an initial treatment with broad spectrum antibiotics for healthcare-associated pneumonia and negative serologic studies, a diagnosis of pneumocystis pneumonia was established using bronchoalveolar lavage. We suggest that rituximab can be an aggravating cause of pneumocystis in patients treated with prednisone.

AB - We report a 51-year-old woman with known SLE on low dose prednisone, recently started on rituximab, who presents with acute respiratory failure and bilateral air space disease. After an initial treatment with broad spectrum antibiotics for healthcare-associated pneumonia and negative serologic studies, a diagnosis of pneumocystis pneumonia was established using bronchoalveolar lavage. We suggest that rituximab can be an aggravating cause of pneumocystis in patients treated with prednisone.

KW - Pneumocystis pneumonia

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=66449129613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=66449129613&partnerID=8YFLogxK

U2 - 10.1016/j.rmedc.2008.12.004

DO - 10.1016/j.rmedc.2008.12.004

M3 - Article

AN - SCOPUS:66449129613

SN - 1755-0017

VL - 2

SP - 134

EP - 136

JO - Respiratory Medicine CME

JF - Respiratory Medicine CME

IS - 3

ER -

Acute respiratory failure and diffuse pulmonary infiltrates four weeks after rituximab therapy

Abstract

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this